About DREAM
October 4, 2014

People

We Are Our People

DREAM was developed by IBM Researcher, Gustavo Stolovitzky in collaboration with Andrea Califano from Columbia University. DREAM Challenges officially commenced in 2006 with a conference that brought together stakeholders in the community. Under the direction of Dr. Stolovitzky, DREAM has grown and thrived over the succeeding years as teams of scientist collaborate from universities, the public sector, and industry. In February 2013, and based on the success of collaborating to run the 2012 Sage Bionetworks/DREAM Breast Cancer Prognosis Challenge, Sage Bionetworks merged its open science efforts with those of DREAM.

The DREAM Challenges have had hundreds of scientists representing over 50 different institutions participating in the organization of different DREAM Challenges through the years. It is this diversity of expertise and ideas that is in our DNA;  it is what makes the DREAM Challenges work.

ibm-200-94 Sage

CU_Anschutz_Med_logoJRC

Leadership

The Team that brings you the DREAM Challenges is diverse. We bring the expertise of many Institutions and disciplines together to bring you the DREAM Challenges.

Gustavo Stolovitsky

Gustavo Stolovitsky

Program Director, Translational Systems Biology and Nanobiotechnology
IBM Thomas J. Watson Research Center, Yorktown Heights, NY
Dr. Stolovitzky received his M.Sc. in Physics (with honors) from the University of Buenos Aires, Argentina (1987) and his Ph.D. in Mechanical Engineering from Yale University (1994), which awarded him the Henry Prentiss Becton Prize for Excellence in Engineering and Applied Sciences. MORE

laraheadshot-3

Lara Mangravite

President
Sage Bionetworks
, Seattle, WA
Sage Bionetwors is focused on the development and implementation of practices for large-scale collaborative biomedical research. Previously, Dr. Mangravite served as Director of the Systems Biology research group where she focused on the application of collaborative approaches to advance understanding of disease biology and treatment outcomes at a systems level with the overriding goal of improving clinical care. MORE